Last reviewed · How we verify
NCT05862792
Liposomal Bupivacaine and Transoral Robotic Surgery
trial testing Liposomal bupivacaine in Oropharyngeal Cancer in 80 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Geisinger Clinic |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 1 June 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 15 January 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Liposomal bupivacaine — full drug profile →
Conditions studied
- Oropharyngeal Cancer — all drugs for Oropharyngeal Cancer →
- Dysphagia, Oropharyngeal — all drugs for Dysphagia, Oropharyngeal →
- Post Operative Pain — all drugs for Post Operative Pain →
- Transoral Robotic Surgery — all drugs for Transoral Robotic Surgery →
Sponsor
Geisinger Clinic
Who can join
18 and older, any sex, with Oropharyngeal Cancer or Dysphagia, Oropharyngeal. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is for patients with oropharyngeal squamous cell carcinoma. We want to learn more about how we can optimize pain control in patients who undergo transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma. Our goal is to determine if a local anesthetic called EXPAREL® (Liposomal Bupivacaine) impacts postsurgical pain and swallow function in patients with oropharyngeal squamous cell carcinoma undergoing TORS. EXPAREL® is an FDA-approved anesthetic drug that provides long-lasting and precise pain relief when injected into the surgical wound. Our study team wants to determine if injecting EXPAREL® into the surgical wound will provide better pain relief and swallow function when compared to patients who do not undergo postoperative EXPAREL® injection. Both options for postoperative pain control are considered standard of care for patients undergoing TORS.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05862792
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Liposomal bupivacaine
Trials testing the same drug.
- NCT06704698 — Postoperative Analgesia Between Paravertebral Block and Epidural Block in Esophageal Surgery · NA · recruiting
- NCT06575699 — Rectus Sheath Block for Analgesia After Gynecological Laparotomy · Phase 4 · completed
- NCT06569953 — Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chron · Phase 4 · recruiting
- NCT06575010 — Exparel v Dexamethasone in RCR · Phase 4 · enrolling by invitation
- NCT06405724 — Comparison of the Ultrasound-guided Paravertebral Nerve Block With Liposomal Bupivacaine Versus Ropivacaine for Post-Sur · Phase 3 · not yet recruiting
Other recruiting trials for Oropharyngeal Cancer
Currently open trials in the same condition.
- NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
- NCT06446713 — PIRATES: Image-guided Hyper-fractioned Dose-escalation With Proton Therapy for Head and Neck Cancer · Phase 1 · recruiting
- NCT06747390 — Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery · Phase 1 · recruiting
- NCT05363709 — BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients · Phase 2 · active not recruiting
- NCT05814549 — A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC) · active not recruiting
Other Geisinger Clinic trials
Trials by the same sponsor.
- NCT07197801 — Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Diso · NA · recruiting
- NCT06936709 — Perioperative Colchicine for TKA · Phase 4 · not yet recruiting
- NCT07042477 — Integrated Telemedicine Program Evaluation · NA · recruiting
- NCT07028398 — CMSL Ambulatory Sensitive Condition Nudge Study 2 · NA · recruiting
- NCT06696066 — PEERS Pilot: Peer Recovery Support Program to Support Engagement in Medication for Opioid Use Disorder · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05862792 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Geisinger Clinic
- Last refreshed: 9 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05862792.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing